Source: Pizzato, M, McCormack, V, Dossus, L, Al-Alem, U, Delpierre, C, Lamy, S, Macciotta, A, Ricceri, F, Mellemkjær, L, Tjønneland, A, Dahm, C C, Antoniussen, C S, Guénel, P, Fournier, A, Frenoy, P,

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

Authors : The Breast Cancer Expert Committee of the National Quality Control Center for Cancer; The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center; The Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association

Subjects: breast cancer; expert consensus; mTOR inhibitor

Source: Cancer InnovCancer Innovation, Vol 4, Iss 3, Pp n/a-n/a (2025)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Guideline for the Management Pathway and Quality Control of Breast Cancer Prevention and Treatment in China's Counties

Authors : Breast Cancer Expert Committee of National Cancer Quality Control Center; Cancer Prevention and Treatment Committee of Healthy China Research Center

Subjects: breast cancer; county‐level; Neoplasms. Tumors. Oncology. Including cancer and carcinogens

Source: Cancer InnovCancer Innovation, Vol 4, Iss 3, Pp n/a-n/a (2025)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Authors : Jiayu Wang; Qingyuan Zhang; Tao Sun

Subjects: advanced breast cancer; endocrine therapy; Neoplasms. Tumors. Oncology. Including cancer and carcinogens

Source: Cancer Commun (Lond)Cancer Communications, Vol 45, Iss 6, Pp 640-653 (2025)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study

Authors : Li Chen; Wen‐Ya Wu; Fei Liang

Subjects: Adult; Paclitaxel; Receptor, ErbB-2

Source: Cancer Commun (Lond)Cancer Communications, Vol 45, Iss 4, Pp 411-421 (2025)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Exploring the Complex Mechanisms of Isoflavones: From Cell Bioavailability, to Cell Dynamics and Breast Cancer

Authors : Ferriere, François; Aasi, Nagham; Flouriot, Gilles ...

Subjects: 0301 basic medicine; 0303 health sciences; Estrogen Receptor alpha

Source: Phytother Res

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

2‐dodecyl‐6‐methoxycyclohexa‐2,5‐diene‐1,4‐dione mediates the effect of ROS‐enhanced PI3K/Akt/mTOR pathway on autophagy in breast cancer

Authors : Linqian Chen; Meifeng Chen; Yan Xie

Subjects: 0301 basic medicine; autophagy; QH301-705.5

Source: FEBS Open BioFEBS Open Bio, Vol 15, Iss 3, Pp 474-489 (2025)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Development and validation of prediction models for sentinel lymph node status indicating postmastectomy radiotherapy in breast cancer: population-based study

Development of 4T1 breast cancer mouse model system for preclinical carbonic anhydrase IX studies

Afadin loss induces breast cancer metastasis through destabilisation of E‐cadherin to F‐actin linkage

Education level and risk of breast cancer by tumor subtype in the EPIC cohort

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

Guideline for the Management Pathway and Quality Control of Breast Cancer Prevention and Treatment in China's Counties

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study

Exploring the Complex Mechanisms of Isoflavones: From Cell Bioavailability, to Cell Dynamics and Breast Cancer

2‐dodecyl‐6‐methoxycyclohexa‐2,5‐diene‐1,4‐dione mediates the effect of ROS‐enhanced PI3K/Akt/mTOR pathway on autophagy in breast cancer

اتصل بنا

اتبع